Adaptive Biotechnologies heads into its third-quarter report with a peculiar setup. Its core clonoSEQ minimal residual disease franchise keeps getting stronger, management has raised its outlook at nearly every turn, and a planned separation of the MRD business from Immune Medicine has given the stock a fresh strategic angle. Yet the headline numbers due after the close on November 4 will look like contraction. The real question is whether the underlying MRD engine is running hot enough to keep beating a guide that management openly built with a cushion.

Wall Street expects a loss of 10 cents a share on revenue of about $71.8 million. That top line would be flat with the prior quarter and roughly 24% below the $94.0 million posted a year ago. The decline contrasts with MRD revenue growth above 50% in recent quarters. That points to lumpy, non-recurring items in the comparison rather than a weakening core business, and management has said it expects no further MRD milestone revenue this year after the $9 million recognized in the first quarter. The loss is expected to narrow by a third from 15 cents a year ago. The whisper number sits at a loss of 7 cents, a modestly higher bar than consensus. It suggests some investors expect cost discipline and margin gains to show up again.

Guidance is the anchor. Management has lifted its full-year MRD revenue outlook from an initial $255 million to $265 million, to $260 million to $270 million, and most recently to $268 million to $278 million. The full-year Street revenue estimate of about $287 million covers the whole company, including Immune Medicine, so it does not line up neatly with the MRD-only range. Still, the pattern of steady upward revisions means another raise has become the expectation, not a bonus. MRD clinical volume guidance has followed the same path, moving from above 30% to at least 35% to 38% to 40%. First-half growth ran in the low 40s, so the full-year range implies a second-half slowdown. Management framed that as prudence against tougher comparisons rather than a forecast of weaker demand. Third-quarter volume growth that holds near 40% would support that reading. A drop into the low 30s would suggest the conservatism was warranted.

The quality of growth matters as much as the pace. Average selling price climbed to $1,360 in the first quarter on the way to a target of about $1,400, and steady progress there would confirm that reimbursement wins are flowing through. Sequencing gross margin reached 70%, and management has since raised its long-term target to 75%, so further expansion is the clearest route to the whisper number. Serial testing pull-through rose from 60% to 75%, helped by the first Epic integration. A further gain, or wider Epic adoption, would show that clonoSEQ is becoming built into ongoing patient monitoring rather than used as a one-off test. Pharma revenue is the main swing factor. Management already flagged a step-down from a strong second quarter, so a soft number there should not alarm anyone unless it comes with weaker study signings or enrollment.

Sentiment has turned noticeably. Readings moved from moderately bearish before the last report to mildly bullish now, and the shares have gained about 18% since then, beating the S&P 500 by more than 14 points. At around $26, the stock sits well above its 200-day moving average near $19.38. It remains comfortably below the post-earnings high of $30.74, so this is not a breakout setup. The market has rewarded the story without fully pricing in perfection.

The central issue is whether MRD volume and pricing hold strongly enough to justify another increase to the $268 million to $278 million range. Updates on the separation process and on any use of the new convertible capital to expand into solid tumors will add context. The narrative stays intact only if the core numbers keep showing that management's caution was a choice and not a warning.